A British Highflier Falters

Bad news continues to plague erstwhile highflier British Biotech PLC, which has a promising broad-spectrum cancer drug, Marimastat. On Apr. 20, it fired Andrew Millar, director of clinical research, for allegedly disclosing confidential data to shareholders. Its shares have fallen to 89 cents from a high of around $5 in May, 1996. The company also said the U.S. Securities & Exchange Commission is investigating press releases it issued in 1995 and 1996.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.